Zheng, et al. have developed an ASGPR-targeting nanovector that delivers sorafenib and siVEGF simultaneously to enhance the targeting ability of the nanodrug delivery system and significantly induce cytotoxicity of three different HCC cell lines [92], which showed the high anti-tumor efficiency as a potential nanovector for targeted delivery to HCC (Figure 2). The gene discussed is ASGR1; the disease is hepatocellular carcinoma.